e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 34

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

Weijun Wang; Zong‐Han Liu; Kang Wang; Hongming Yu; Yuqiang Cheng; Yan‐Jun Xiang; Jin-Kai Feng; Liping Zhou · 2023 · Cancer Medicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 inhibitors (T-L-P) versus TACE combined with lenvatinib (T-L) or TACE alone. METHOD: Data were collected from 204 patients with unresectable recurrent HCC who received T-L-P, T-L, or TACE alone at three medical centers from January, 2019 to December, 2020 for analysis. The survival outcomes, tumor response, and adverse events were compa

Abstract by Weijun Wang; Zong‐Han Liu; Kang Wang; Hongming Yu; Yuqiang Cheng; Yan‐Jun Xiang; Jin-Kai Feng; Liping Zhou, Cancer Medicine (2023) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1002/cam4.5880